Autoimmune atherosclerosis in 3D: How it develops, how to diagnose and what to do

Z. Szekanecz, G. Kerekes, Edit Végh, Zsófia Kardos, Zsuzsa Baráth, László Tamási, Yehuda Shoenfeld

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Autoimmune-inflammatory rheumatic diseases, such as rheumatoid arthritis (RA) have been associated with autoimmune atherosclerosis leading to increased cardiovascular risk. Traditional risk factors, genetics, as well as the role of systemic inflammation including inflammatory cells, cytokines, chemokines, proteases, autoantibodies, adhesion receptors and others have been implicated in the development of these vascular pathologies. Cardiovascular risk may be determined by the use of currently available tools. In addition, non-invasive assessment of vascular pathophysiology by imaging, as well as laboratory biomarkers can help to refine risk assessment. With respect to prevention and therapy, traditional vasculoprotection using statins, ACE inhibitors, aspirin should be applied to patients at risk. Non-steroidal antiinflammatory drugs and corticosteroids may be pro-atherogenic, on the other hand, they may also be beneficial due to their anti-inflammatory nation. Traditional and biologic DMARDs may have significant vascular and metabolic effects. Decreasing inflammatory activity by any of these agents may lead to better CV outcome. The official EULAR recommendations on the assessment and management of cardiovascular disease in arthritides may guide the rheumatologist during the process of CV screening, prevention and treatment.

Original languageEnglish
JournalAutoimmunity Reviews
DOIs
Publication statusAccepted/In press - Mar 2 2016

Fingerprint

Blood Vessels
Atherosclerosis
Anti-Inflammatory Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Antirheumatic Agents
Rheumatic Diseases
Chemokines
Angiotensin-Converting Enzyme Inhibitors
Autoantibodies
Aspirin
Arthritis
Rheumatoid Arthritis
Adrenal Cortex Hormones
Peptide Hydrolases
Cardiovascular Diseases
Biomarkers
Pathology
Cytokines
Inflammation
Therapeutics

Keywords

  • Arthritis
  • Atherosclerosis
  • Autoimmunity
  • Biologics
  • Cardiovascular disease
  • Risk assessment

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Autoimmune atherosclerosis in 3D : How it develops, how to diagnose and what to do. / Szekanecz, Z.; Kerekes, G.; Végh, Edit; Kardos, Zsófia; Baráth, Zsuzsa; Tamási, László; Shoenfeld, Yehuda.

In: Autoimmunity Reviews, 02.03.2016.

Research output: Contribution to journalArticle

Szekanecz, Z. ; Kerekes, G. ; Végh, Edit ; Kardos, Zsófia ; Baráth, Zsuzsa ; Tamási, László ; Shoenfeld, Yehuda. / Autoimmune atherosclerosis in 3D : How it develops, how to diagnose and what to do. In: Autoimmunity Reviews. 2016.
@article{0b5b2c03b339430cb2f53f94cc489092,
title = "Autoimmune atherosclerosis in 3D: How it develops, how to diagnose and what to do",
abstract = "Autoimmune-inflammatory rheumatic diseases, such as rheumatoid arthritis (RA) have been associated with autoimmune atherosclerosis leading to increased cardiovascular risk. Traditional risk factors, genetics, as well as the role of systemic inflammation including inflammatory cells, cytokines, chemokines, proteases, autoantibodies, adhesion receptors and others have been implicated in the development of these vascular pathologies. Cardiovascular risk may be determined by the use of currently available tools. In addition, non-invasive assessment of vascular pathophysiology by imaging, as well as laboratory biomarkers can help to refine risk assessment. With respect to prevention and therapy, traditional vasculoprotection using statins, ACE inhibitors, aspirin should be applied to patients at risk. Non-steroidal antiinflammatory drugs and corticosteroids may be pro-atherogenic, on the other hand, they may also be beneficial due to their anti-inflammatory nation. Traditional and biologic DMARDs may have significant vascular and metabolic effects. Decreasing inflammatory activity by any of these agents may lead to better CV outcome. The official EULAR recommendations on the assessment and management of cardiovascular disease in arthritides may guide the rheumatologist during the process of CV screening, prevention and treatment.",
keywords = "Arthritis, Atherosclerosis, Autoimmunity, Biologics, Cardiovascular disease, Risk assessment",
author = "Z. Szekanecz and G. Kerekes and Edit V{\'e}gh and Zs{\'o}fia Kardos and Zsuzsa Bar{\'a}th and L{\'a}szl{\'o} Tam{\'a}si and Yehuda Shoenfeld",
year = "2016",
month = "3",
day = "2",
doi = "10.1016/j.autrev.2016.03.014",
language = "English",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",

}

TY - JOUR

T1 - Autoimmune atherosclerosis in 3D

T2 - How it develops, how to diagnose and what to do

AU - Szekanecz, Z.

AU - Kerekes, G.

AU - Végh, Edit

AU - Kardos, Zsófia

AU - Baráth, Zsuzsa

AU - Tamási, László

AU - Shoenfeld, Yehuda

PY - 2016/3/2

Y1 - 2016/3/2

N2 - Autoimmune-inflammatory rheumatic diseases, such as rheumatoid arthritis (RA) have been associated with autoimmune atherosclerosis leading to increased cardiovascular risk. Traditional risk factors, genetics, as well as the role of systemic inflammation including inflammatory cells, cytokines, chemokines, proteases, autoantibodies, adhesion receptors and others have been implicated in the development of these vascular pathologies. Cardiovascular risk may be determined by the use of currently available tools. In addition, non-invasive assessment of vascular pathophysiology by imaging, as well as laboratory biomarkers can help to refine risk assessment. With respect to prevention and therapy, traditional vasculoprotection using statins, ACE inhibitors, aspirin should be applied to patients at risk. Non-steroidal antiinflammatory drugs and corticosteroids may be pro-atherogenic, on the other hand, they may also be beneficial due to their anti-inflammatory nation. Traditional and biologic DMARDs may have significant vascular and metabolic effects. Decreasing inflammatory activity by any of these agents may lead to better CV outcome. The official EULAR recommendations on the assessment and management of cardiovascular disease in arthritides may guide the rheumatologist during the process of CV screening, prevention and treatment.

AB - Autoimmune-inflammatory rheumatic diseases, such as rheumatoid arthritis (RA) have been associated with autoimmune atherosclerosis leading to increased cardiovascular risk. Traditional risk factors, genetics, as well as the role of systemic inflammation including inflammatory cells, cytokines, chemokines, proteases, autoantibodies, adhesion receptors and others have been implicated in the development of these vascular pathologies. Cardiovascular risk may be determined by the use of currently available tools. In addition, non-invasive assessment of vascular pathophysiology by imaging, as well as laboratory biomarkers can help to refine risk assessment. With respect to prevention and therapy, traditional vasculoprotection using statins, ACE inhibitors, aspirin should be applied to patients at risk. Non-steroidal antiinflammatory drugs and corticosteroids may be pro-atherogenic, on the other hand, they may also be beneficial due to their anti-inflammatory nation. Traditional and biologic DMARDs may have significant vascular and metabolic effects. Decreasing inflammatory activity by any of these agents may lead to better CV outcome. The official EULAR recommendations on the assessment and management of cardiovascular disease in arthritides may guide the rheumatologist during the process of CV screening, prevention and treatment.

KW - Arthritis

KW - Atherosclerosis

KW - Autoimmunity

KW - Biologics

KW - Cardiovascular disease

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=84962137597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962137597&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2016.03.014

DO - 10.1016/j.autrev.2016.03.014

M3 - Article

C2 - 26979271

AN - SCOPUS:84962137597

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

ER -